Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultra-Fast CD19 CAR-T for Refractory SLE
NCT07233642Phase 1Recruiting
- Sponsor
- Children's Hospital, Zhejiang University School of Medicine
- Start
- Nov 2025
- Primary completion
- May 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD19 CAR-T cells in systemic lupus erythematosus (SLE), sponsored by Children's Hospital, Zhejiang University School of Medicine. Primary endpoints: Safety of CAR-T cell therapy at 3 months, Systemic Lupus Erythematosus Disease Activity Index 2000 at 6 months and 5 more. Started Nov 2025; status: recruiting.
02
Drugs
CD19 CAR-T cells
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07233642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07233642.